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Abstract: Elevated levels of nuclear Y-box binding protein 1 (YB-1) are linked to poor prognosis
in cancer. It has been proposed that entry into the nucleus requires specific proteasomal cleavage.
However, evidence for cleavage is contradictory and high YB-1 levels are prognostic regardless of
cellular location. Here, using confocal microscopy and mass spectrometry, we find no evidence
of specific proteolytic cleavage. Doxorubicin treatment, and the resultant G2 arrest, leads to a
significant increase in the number of cells where YB-1 is not found in the cytoplasm, suggesting that
its cellular localisation is variable during the cell cycle. Live cell imaging reveals that the location
of YB-1 is linked to progression through the cell cycle. Primarily perinuclear during G1 and S
phases, YB-1 enters the nucleus as cells transition through late G2/M and exits at the completion of
mitosis. Atomistic modelling and molecular dynamics simulations show that dephosphorylation
of YB-1 at serine residues 102, 165 and 176 increases the accessibility of the nuclear localisation
signal (NLS). We propose that this conformational change facilitates nuclear entry during late G2/M.
Thus, the phosphorylation status of YB-1 determines its cellular location.
Keywords: YB-1; cell cycle; nuclear translocation; atomistic modelling; phosphorylation
1. Introduction
Y-box-binding protein 1 (YB-1; encoded by YBX1), is a multifunctional protein involved in
numerous biological processes including cell cycle progression, DNA repair, and drug resistance.
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There have been a number of reports linking YB-1 cleavage and subsequent nuclear translocation to
poor cancer prognosis, reviewed in [1–9]. When in the nucleus, YB-1 acts as a transcription factor where
it transactivates the growth promoting genes c-ERBB2 [10] and EGFR [11] and also downregulates
the death-promoting genes TP53 [12] and FAS [13]. Nuclear translocation of YB-1 is reported to
occur in a cell cycle dependent fashion [14,15] and in response to a range of stressors including
DNA damaging agents [16–18]. As tumour cells are thought to be under constant stress due to the
accumulation of mutations, the significance of nuclear YB-1 in cancer has been the focus of ongoing
investigations. Nuclear YB-1 has been shown to be a negative prognostic marker in patients with
a range of cancers including synovial sarcoma [19], breast [3], prostate [2] and non-small cell lung
cancers [1]. However, other studies have found that it is the overall level of YB-1 protein (and mRNA),
rather than its nuclear location, which is associated with high grade cancers [6,20–22].
Reports that increased nuclear YB-1 is linked to both tumour progression and drug resistance
stimulated investigations into the molecular mechanism underpinning YB-1 transcriptional activation.
A model of proteasome-mediated cleavage by the 20S proteasome through sequence-specific
endoproteolytic cleavage was proposed [7,8]. Cleavage would allow the N-terminal region of
YB-1 to be free of the dominant cytoplasmic retention signal (CRS; aa 247–267) [23], thus enabling
the nuclear localisation signal (NLS; aa 186–205 [24]) to direct the cleaved N-terminal product to the
nucleus (Supplementary Figure S1A). It was suggested that this proteolytic activation is associated with
genotoxic stress, and that cleaved nuclear YB-1 is a distinct species with transcription factor activity
compared to the full-length cytoplasmic YB-1 [7]. Subsequent domain mapping revealed the presence
of three additional NLS at aa 149–156, 185–194 and 276–292 [9], with part of the latter located within the
CRS (aa 264–290) previously proposed by Bader et al. [24]. Van Roeyen et al. also reported the presence
of a C-terminal fragment in the nucleus following proteolytic cleavage [9], rather than the N-terminus,
as previously reported [7]. We have sequenced nuclear YB-1 using mass spectrometry and found no
evidence of cleavage at the aa 219/220 site [25]. Due to these inconsistencies within the literature we
decided to further investigate whether we could detect any evidence of specific proteolytic cleavage.
In this paper we used YB-1 plasmids with tags at each end of the protein and carried out
immunofluorescent (IF) labelling after transfection of several cancer cell lines, either untreated or
treated with doxorubicin (DOX), or paclitaxel (PTX). We also used confocal and live cell imaging and
in some cases mass spectrometry of purified YB-1 protein. Our results provide no compelling evidence
of specific cleavage at the site originally proposed in the 20S model [7,8]. We do however confirm that
YB-1 migrates to the nucleus but we make the novel observation that this occurs during late G2/M
coinciding with the onset of nuclear membrane disruption. Finally, we provide mechanistic evidence
using 3D structural modelling, that the phosphorylation status of YB-1 alters the accessibility of both
the cytoplasmic retention signal (CRS) and the nuclear localisation signal (NLS) and confirm this
experimentally by showing that when these serine residues are mutated, YB-1 remains in the nucleus.
We propose that dynamic changes in the phosphorylation status of specific residues of YB-1 and the
resultant conformational fluctuation in the accessibility of both the NRS and the CRS, regulates the
cellular location of YB-1.
2. Results
2.1. Full Length YB-1 is Present in Both Nuclear and Cytoplasmic Compartments
To determine whether YB-1 is full length or cleaved upon nuclear translocation we transfected
three cancer cell lines (A549, H1299 and Saos-2) with a plasmid carrying both N- and C-terminal labels
(HAYB-1FLAG, Supplementary Figure S1A) and quantitated the location of each tag using IF labelling
of tag-specific antibodies. Confocal images of representative cells from each cell line are shown in
Figure 1A. Both anti-HA (red) and anti-FLAG (green) antibodies detecting the N and C terminus of
HAYB-1FLAG respectively, were found in the cytoplasm and the nucleus of all three cell lines and these
two labels are co-localised (Figure 1A, lower panels). We quantitated the intensity of HAYB-1 and
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YB-1FLAG in at least 100 cells from each cell line. The nucleus and cytoplasm were defined using masks
created by the imaging software (Figure 1B). Results from this analysis show that the average ratio of
intensity per area of both HAYB-1 and YB-1FLAG is 1.0671 (range 0.8376–1.2966) for the three cell lines in
either the nucleus or cytoplasm (Figure 1C), confirming that these two labels co-localise.
Figure 1. Full length YB-1 is present in the nuclear and cytoplasmic compartments. (A) Shows the
nuclear and cytoplasmic location of HAYB-1FLAG in A549, H1299 and Saos-2 cells. Top row shows
anti-HA which detects the N-terminus of HAYB-1FLAG, middle row shows anti-FLAG which detects the
C-terminus of HAYB-1FLAG and the bottom row shows the merged image. The nucleus is stained with
Hoechst, anti-HA (green) and anti-FLAG (red). (B) shows examples of the nuclear and cytoplasmic
mask used to determine cellular location of HAYB-1FLAG. (C) the fluorescence intensity/area for anti-HA
and anti-FLAG using this mask for > 100 cells in all three cell lines. Each dot represents the intensity/area
for anti-HA and anti-FLAG for each cell and the slope of the line is indicated.
This was shown further by performing western blot analyses on whole cell lysates as well as
cytoplasmic and nuclear fractions. Full length YB-1 protein (49kDa) is present in both cellular fractions
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(Supplementary Figure S2B, Tables S1–S3). There is no obvious evidence of enrichment for a smaller
species (~32kDa) consistent with 20S proteasomal cleavage.
In further confirmation of this conclusion, we performed LC-MS/MS analysis of endogenous
YB-1 immunopurified from the cytoplasm and nuclei of A549 and MDA-MB-231 cells. Results show
(Supplementary Figure S1B; Table S5) that the peptides assigned to YB-1 from two independent runs
cover the length of YB-1. Importantly, tryptic peptides (RPQYSNPPVQGEVMEGADNQGAGEQRPVR)
spanning the proposed 20S proteasomal cleavage site (Supplementary Figure S1C) were identified in
immunopurified YB-1 from cytoplasm (3/4 samples) and nucleus (3/4 samples; Supplementary
Figure S8). Mass spectrometry indicates that full length YB-1 is in the nucleus of A549 and
MDA-MB231 cells.
2.2. Specific Proteosomal Cleavage of YB-1 does not Occur in Response to Treatment with Doxorubicin or Paclitaxel
We next asked whether treatment with drugs causing genotoxic stress promotes YB-1 cleavage.
We used either the topoisomerase inhibitor doxorubicin (DOX) or the microtubule inhibitor paclitaxel
(PTX). We chose these two different treatments due to their differential effects on the cell cycle.
DOX causes replicative stress leading to G2 phase arrest [26] and PTX causes cells to arrest in late
G2/M and eventually the cells undergo death by mitotic catastrophe [27,28]. The dosages used for
each of these drugs was chosen based on their IC50 values (Figure S2A). Cells were treated with
either drug 24 hours after transfection with HAYB-1FLAG and IF analysis was carried out. Again,
both anti-HA (red) and anti-FLAG (green) antibodies detecting the N and C terminals of HAYB-1FLAG
were found in the cytoplasm and the nucleus of all three cell lines (Figure 2A). Quantitation of >100
cells was performed as above and the results show that the average ratio of intensity per area of
both HAYB-1 and YB-1FLAG is 1.13 (range 0.9017–1.3561) for the three cell lines treated with either
DOX or PTX (Figure 2B). These data show that both labels are present in equal intensities, providing
evidence that YB-1 is full-length. In order to ensure that this effect is not due to differences in antibody
specificity, we repeated these experiments with the opposite secondary antibodies (i.e., Alexa Fluor
568 (red) anti-rabbit (HA) /Alexa Fluor 488 (green) anti-mouse (FLAG) compared to Alexa Fluor 488
(green) anti-rabbit (HA)/Alexa Fluor 568 (red) anti-mouse (FLAG). These data are shown in Figure S3;
quantification of signal intensities in Tables S6 and S7. The average ratios of the 2 fluorochromes is 1.02
(range: 0.54–1.31) shown in Figure S3B, essentially confirming the data in Figure 2B, implying that
equal amounts of each tag are present in both compartments and arguing against proteolysis. There
is one exception and that is with DOX treated nuclear YB-1 in the A549 cells where the ratio is ~0.5.
suggesting relative loss of the C-terminus; but this was not consistent across experiments.
Cellular fractionation and immunoblotting confirm the presence of full length YB-1 in both nuclear
and cytoplasmic compartments (Supplementary Figure S2). The blots also reveal the presence of
smaller YB-1 fragments. In both the A549 and H1299 cells they are primarily associated with the
whole-cell (WCL) lysates. In the merged western blots for these cells, the fragments appear as green,
suggesting that the C-terminal end of the protein (with the red tag) is no longer present. In the Saos-2
cells, additional fragments are evident in the nuclear lysates. Again, in the merged image these bands
are green, suggesting the absence of the C-terminus. There is also a red band in the WCL fraction
at ~20 kDa that is present following treatment with either PTX or DOX, suggesting the absence of
the N-terminus (carrying the green tag). The size of these smaller bands is not consistent with that
of a fragment proposed in the cleavage model [7]. To try and understand whether these fragments
were influenced by the location of the tags, we carried out the same nuclear fractionation experiment
with FLAGYB-1HA construct. These data are shown in Figure S4. Again, we find the presence of
additional fragments in the WCL and nuclear fragments, which are more numerous in the H1299 cells.
Again, none of these fragments is consistent with proteolytic cleavage at the 219/220 site.
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Figure 2. Full length YB-1 is present in both compartments following DNA damage. (A) shows the
nuclear and cytoplasmic location of HAYB-1FLAGin A549, H1299 and Saos-2 cells treated with DOX
or PTX. Top row shows anti-HA which detects the N-terminus of tagged HAYB-1FLAG, middle row
shows anti-FLAG which detects the C-terminus of tagged HAYB-1FLAG and the bottom row shows the
merged image. The nucleus is stained with Hoechst, anti-HA (green) and anti-FLAG (red). (B) the
fluorescence intensity/area for anti-HA and anti-FLAG using masks to differentiate the nucleus and the
cytoplasmic compartments for > 100 cells in all three cell lines. Each dot represents the intensity/area
for anti-HA and anti-FLAG for each cell. The red dotted line represents the line of best fit. The slope of
the line is indicated. (C) shows example of the masks with either the presence or absence of cytoplasmic
staining of HAYB-1FLAG using anti-HA and anti-FLAG in A549, H1299 and Saos-2 cells treated with
DOX. (D) Shows the percentage of acytoplasmic cells; i.e. those that did not show cytoplasmic labelling
with either anti-HA or anti-FLAG, indicating that YB-1 was not present in the cytoplasm of these cells.
Chi-square test was used to determine significance, * p < 0.05, **** p <0.0001.
Of note, when we quantitated the cellular location of HAYB-1FLAG in response to DOX treatment,
we surprisingly found many cells where YB-1 could not be detected in the cytoplasm (acytoplasmic;
Figure 2C, D). As DOX leads to arrest in G2, this led us to consider the possibility that, in addition to
the response to DNA-damaging agents, the nuclear location of YB-1 may be linked to cell cycle phase;
and specifically, to the G2/M phases.
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2.3. Nuclear Localisation of YB-1 Occurs during Late G2 Phase of the Cell Cycle
To investigate this possibility, A549 cells were transfected with the HAYB-1FLAG plasmid and
subsequently stained with antibodies to both HA, FLAG and the nuclear envelope marker Lamin B1
to determine YB-1 location. As shown in Figure 3A, the cellular location of YB-1, as demonstrated
by IF analysis of the HAYB-1FLAG-transfected cell varies. Due to the fact that cells round up in early
mitosis some of this variation appears to be linked to the cell cycle. To investigate this further, we
carried out live cell imaging to identify cell cycle phases at single cell resolution using A549 FUCCI
cells carrying both mCherry (red)-cdt1 and mVenus (green)-geminin tags [29]. By linking these two
proteins to fluorescent labels, cell cycle progression can be visualised in real time [30]. These cells were
transfected with a YB-1 construct carrying the blue fluorescent protein 2 (YB-1EBFP2) marker. The data
(Figure 3B) show that during G1, YB-1 EBFP2 is cytoplasmic (as shown by the red (cdt1) nucleus) but
it begins to enter the nucleus in the G2 phase (as shown by the green (geminin) nucleus). During M
phase, YB-1 EBFP2 (blue) appears centrally in the cell (Figure 3B, arrowed). During the earliest stage of
mitosis (prophase) the paired copies of DNA condense and the nuclear envelope begins to disintegrate,
enabling the DNA pairs to align with the central axis of the cell. Towards the end of mitosis, as the cell
moves into telophase, the two daughter cells move into G1 and YB-1 is again present in the cytoplasmic
compartment (Figure 3B).
Figure 3. YB-1 translocates into the nucleus in the late G2 phase of the cell cycle. (A) Mid z-stack slices
(0.2 µm) showing cellular location of HAYB-1FLAG (yellow) in A549 cells. LaminB1 (magenta) marks the
nuclear envelope. (B) Illustrates the cellular location of YB-1eBFP2 in different phases of the cell cycle in
A549 FUCCI cells transfected with YB-1eBFP(blue); G1 marked by cdt1(red), S/G2 marked by geminin
(green). The white arrow shows a mitotic cell where YB-1 (blue) fills the whole cell.
To confirm that the observed movement of YB-1 from the cytoplasm to the nucleus during G2/M
is not an artefact of exogenously expressed YB-1, we repeated this experiment in A549 cells that were
synchronised using a double thymidine block and samples taken at 0, 1, 2, 3, 4 and 5 hours followed by
15 min time intervals up to 8 hours after release of the second block. These data are shown in Figure 4.
The upper row of this figure is a projection of a z-stack of adjacent 0.2 µm optical slices acquired by
confocal microscopy. The rows below represent top, middle and bottom slices of each z-projection.
As previously reported, YB-1 can be found in both the nucleus and/or cytoplasm, and is often found in
the perinuclear region of cells [4,20,22,31].
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Figure 4. Cellular location of YB-1 is dependent on cell cycle phase. The top row are z-projections of 0.2 µm slices of synchronised A549 cells at sequential phases of
the cell cycle. The second row shows the top slice, the third row shows the middle slide and the last row shows the bottom slices of each stack respectively. YB-1
(shown in green) is cytoplasmic in G1, becomes increasingly perinuclear during G2 and moves into the nucleus during prophase and remains there until telophase
when it appears to be outside the nucleus. Lamin B1 is shown in red. Scale bar: 10 µm.
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Interestingly, when YB-1 is perinuclear, when visualised using conventional light microscopy it
often appears to be nuclear. Comparison between the z-projection of a cell in G1 (top left-hand panel)
and the slices shown below provides insight into why YB-1 may appear to be nuclear when viewed
two-dimensionally. The green punctate staining that appears nuclear on the projected stack in the first
column is on the outside of the nuclear envelope. YB-1 is found in the cytoplasm during G1 (Figure 4;
column 1) and increasingly localises to the perinuclear region during the G2 phase (Figure 4; column
2). We used this localisation, clearly visible by microscopy, as a marker of G2. As the cells progress into
the mitotic phase of the cell cycle, YB-1 becomes localised to the nucleus. This is evident (Figure 4;
column 3) in prophase which is the first phase of mitosis and continues until anaphase (Figure 4;
column 6). Prophase is characterised by disruption of the nuclear envelope (as evidenced by lamin B1
staining (shown in red)). YB-1 remains nuclear until the nuclear envelope is re-established at the end
of anaphase and begins to return to the cytoplasmic compartment during telophase (the last stage of
mitosis; Figure 4; column 7).
2.4. Nuclear Localisation of YB-1 is Dependent on Phosphorylation Status
Given that our data suggest that YB-1 nuclear translocation varies with cell cycle phase, we wished
to understand how this process is controlled. Previously, phosphorylation of serine 102 [32–35], as well
as phosphorylation of both serines 165 and 176 [36,37] have been shown to play a role in oncogenic
activation. Given that two of these residues are close to the nuclear localisation signal (NLS; see Figure
S1A) we hypothesised that the phosphorylation status of these residues would alter the tertiary structure
of YB-1 and hence the accessibility of the nuclear localisation signal (NLS). Increased accessibility of
the NLS and/or reduced accessibility of the CRS would theoretically result in an increased amount
of YB-1 present in the nucleus. To test this hypothesis, we performed atomistic modelling of YB-1 to
measure the solvent accessibility surface area (SASA) in Å2 of the nuclear localisation signal (NLS),
using the I-TASSER pipeline followed by molecular dynamics (MD) simulations. Of the five potential
models that were generated by the I-TASSER server (Figure S6), model 3 was selected as the predicted
cold shock domain of this model was close to the known NMR structure of YB-1 [38].
As shown in the graph at the far right of Figure 5A, the accessible surface area of the NLS in
YB-1 where all three serine residues are phosphorylated (YB-1phos; black line) is reduced compared
to unphosphorylated (YB-1unphos; red line). Thus, phosphorylation reduces access to the NLS,
increasing the likelihood of YB-1 remaining in the cytoplasm. Modelling of individual serine mutations
(S102A, S165A and S176A; red, brown and green lines) shows that the SASA values for the mutants are
increased. Therefore, the accessibility of the NLS (shown in blue on each of the models) is dependent on
the phosphorylation of these serine residues. Conversely, Figure 5B shows that phosphorylation of these
serine residues (YB-1phos) leads to an increase in the accessibility of the cytoplasmic retention signal
(CRS; shown in orange in the models). Again, perturbation of this phosphorylation in the mutants
reduces the SASA value of the CRS. The predictions from this modelling were confirmed by IF labelling
of HA-tagged YB-1 plasmid constructs containing alanine mutations at each of these three serine
residues (S102, S165 and S176) transfected into either A549/FUCCI or HCT116 cells. The subcellular
location of HA-tagged YB-1 was carried out by confocal analysis of Z-stacks using the colour-profiling
tool in Fiji2. Representative confocal images of HA-YB-1 and each of the three HA-tagged YB-1
serine-to-alanine mutants are shown in Figure 5C, where nuclear localisation of HA-YB-1 (green) is
clearly evident in the mutants. Quantification of the IF analysis in > 100 cells transfected the mutants
(Figure 5C, graphs) reveals the number of cells with nuclear YB-1 is significantly increased (p < 0.0001)
compared to wild type (wt)YB-1. The inability of these residues to be phosphorylated reduces the
accessibility of the CRS and YB-1 remains nuclear. To determine whether this effect was seen in mutants
where the acidic charge of the mutation was maintained, we carried out live cell imaging of cells where
we had either mutated S176 alone or together with S165 to an aspartic acid (D) residue. Following
transfection with the YB-1eBFPconstruct, live-imaging showed that YB-1 remains in the cytoplasm in
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contrast to the alanine mutants, in support of our hypothesis. Of note, these mutations led to cell death
as they begin to enter mitosis (Figure S7).
Figure 5. Phosphorylation of serine residues affects both NLS and CRS accessibility. (A) the solvent
accessible surface area (SASA; blue) of the nuclear localisation signal (NLS; residues 183–205) in (from
left to right) YB-1unphos, where the serine residues are not phosphorylated; YB-1 with serine 102 mutated
to an alanine (YB-1S102A); YB-1S165A; YB-1S176A. A model of the NLS SASA when all serine residues are
phosphorylated (YB-1phos) is shown on the right. The graph on the far right shows the SASA range for
each of the models generated with NACCESS. (B) the solvent accessible surface area (SASA; orange)
of the cytoplasmic retention signal (CRS; residues 247–267) in (from left to right) YB-1unphos, where
the serine residues are not phosphorylated; YB-1 with serine 102 mutated to an alanine (YB-1S102A);
YB-1S165A; YB-1S176A. A model of the CRS SASA when all serine residues are phosphorylated (YB-1phos)
is shown on the right. The graph on the far right shows the SASA range for each of the models generated
with NACCESS. C, shows (from left to right) confocal images of HCT116 cells with HA-tagged wild
type (wt)YB-1 (green); HA-tagged YB-1S102A; YB-1S165A and YB-1S176A. Cell nuclei are stained with
Hoechst (blue). The graphs on the right-hand side show the quantification of the percentage of cells
with nuclear YB-1 in both HCT119 and A549_FUCCI cells. Each circle represents one experiment where
at least 100 cells were analysed. The increase in the percentage of cells with nuclear YB-1 between those
transfected with wtYB-1 or with a plasmid containing serine to alanine mutations, in both cell lines is
highly significant (p < 0.0001).
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Our results suggest a model in which dephosphorylation of YB-1 increases NLS exposure and
leads to nuclear localisation, whereas YB-1 phosphorylation increases CRS exposure resulting in
increased retention in the cytoplasm. To confirm that dephosphorylation of endogenous YB-1 does
occur during the cell cycle, we carried out western blotting using either an antibody to wtYB-1 [25] or
to pYB-1S102 on synchronised A549 cells. The timepoints that were chosen are based on the cell cycle
progression of the A549 FUCCI cells following release from a double thymidine block, as shown in
Figure S5. These data are shown in Figure 6; quantification of signal intensities contained in Table S4.
Figure 6. Western Blots from A549 cells following release from double thymidine block. Timepoints at
which cells were harvested are shown below each of the blots. (A) YB-1, as detected by rabbit anti-YB-1
polyclonal antibody is shown in green. β-actin, as detected with a mouse anti-β-actin antibody is shown
in red. (B) YB-1S102, as detected by rabbit anti-phospho-YB1ser102 (Cell Signaling Technology, Danvers,
MA, USA) is shown in green. β-actin, as detected with a mouse anti-β-actin antibody is shown in red.
The last two lanes show treatment with si-YB-1 5′-GGUCCUCCACGCAAUUACCAGCAAA-3′) or
a scrambled si-Control 5’-CCACACGAGUCUUACCAAGUUGCUU-3 from Invitrogen. (C) Ratio of
pYB-1S102/YB-1 in A549 cells post 2T block. Densitometries for these westerns is shown in Table S4
(Supplementary Materials).
They confirm that despite levels of wtYB-1 remaining constant throughout the cell cycle (Figure 6A),
phosphorylation levels of YB-1 as detected by the rabbit polyclonal against phosphorylated S102
(pS102) are increased during early S phase (0–5.5 h), followed by a decrease in the late S and G2 phases
(6–7 h), and then an increase in M phase (9 h) (Figure 6B,C for quantitation relative to β actin).
3. Discussion
Proteolytic cleavage has been reported to occur prior to nuclear translocation [7–9]. Elevated levels
of YB-1 have been linked to oncogenic activity and poor prognosis in a range of cancers [1–6,20,22].
Previous analysis carried out by us does not support specific proteolytic cleavage at the aa 219/220 site [25].
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The evidence regarding the details of proteolytic cleavage are contradictory with both N- and C-terminal
fragments being reported as translocating to the nucleus by different groups [7,9]. To address these
discrepancies, we use IF confocal analysis of three cancer cell lines transfected with a plasmid construct
carrying epitopes to both an N-terminal HA and a C-terminal FLAG (HAYB-1FLAG) to determine whether
this would provide evidence for cleavage. We find equal proportions of both epitopes suggesting that
only full length YB-1 is present in the nucleus and the cytoplasm of cells and that this ratio does not
change in response to treatment with either DOX or PTX. These results are confirmed by LC-MS/MS
analyses of endogenous protein, where a tryptic peptide spanning the proposed site at aa 219/220 targeted
by the 20S proteasome [5,7,9] was detected. Western Blot analysis of subcellular fractions did reveal the
presence of smaller fragments. However, the size of these fragments is not consistent with the predicted
proteasomal cleavage product, which would run at ~32 kDa [7,9].
Specific cleavage was originally reported to occur in response to treatment with bovineα-thrombin
in endothelial cells in vitro [23]. Subsequently, cleavage via the 20S proteasome was reported to take
place in YB-1 purified from rabbit reticulocyte lysate, in murine fibroblasts [7] and in rat mesangial
cells [9], in response to a range of treatments including DOX. However, neither cleavage nor nuclear
localisation occurred following treatment with taxol [7], a result supported by our data. Of note, the
concentrations of DOX that we used were based on the IC50 values (see Figure S2A) which is ~two
orders of magnitudes less (0.005 µg/mL) than the 0.6 µg/mL previously used [7,9]. In our hands the
percentage of surviving cells at the higher dose was drastically reduced, as shown in Figure S2A. The use
of this lower dose is in line with that used previously [26,39]. The differences between our results and
those previously published [7,9,23] may be due to both the difference in the DOX concentration and to
the response of the different cell lines used in these studies. It is also possible that the tags we used (HA
and FLAG) could alter putative site-specific cleavage patterns. However, this seems unlikely as Sorokin
et al. showed that cleavage of ectopically expressed HA-YB-1 by the 20S proteasome produced both 32
kDa and 22 kDa protein species [7] in untreated and DOX treated cells and the generation of these two
species was blocked following treatment with the proteasome inhibitor MG132. Similarly, van Roeyen
et al. demonstrated that proteasomal cleavage of GFP-tagged YB-1 takes place in response to DOX
treatment [9]. Both of these reports illustrate that neither the N-terminal nor C-terminal tags interfere
with either cleavage or nuclear import of YB-1.
Our finding that the cellular location of YB-1 is cell cycle dependent is in line with earlier
reports [14,15,21,40–42]. YB-1 has been shown to transcriptionally activate mRNAs for the cyclins
CCNA1 and CCNB1 [14] as well as CDC6 [40]. This finding was further extended by bioinformatic
analysis to reveal that YB-1 binds to the promotor regions of E2F target genes including CDC6, CCND1
and CDK1 [21] in human cancer cells, thus driving cell cycle progression. Most recently, Kotake et al.
(2017) used a Rb family triple knockout (TKO) model to investigate the role of YB-1 in cell cycle phases
other than G1. They showed that in this model silencing YB-1 led to a G2/M phase arrest and the
repression of CCND1 [15]. In the same paper, RIP-CHIP assay showed YB-1 to be associated with the
mRNA of multiple cell-cycle genes including that of G2/M phase regulators [15]. These findings are in
line with our finding that YB-1 moves into the nucleus during the G2/M transition, potentially to bind
with mRNAs identified by Kotake et al [15]. In line with this, nuclear YB-1 has been shown to interact
directly with the cyclin A2 promoter leading to a downregulation of cyclin A2 mRNA expression in
zebrafish [42]. In addition to this transcriptional role, YB-1 may also play a post-translational regulatory
role. These same authors demonstrate that presence of YB-1 in the nucleus is driven by a circadian
clock mechanism and involves the SUMOylation of YB-1 [42]. YB-1 has been shown to be ‘nuclear’
in 5% of exponentially growing HeLa cells, 6–8 hours following release from lovastatin-induced G1
arrest [14]. As lovastatin activates p21CIP1 and p27ink4a cyclin inhibitory proteins at or near the G1/S
phase boundary [43,44], the timing would be consistent with our data that nuclear translocation of
YB-1 occurs in late S phase or G2 and then into mitosis (M). This is further supported by a subsequent
paper [41], where the authors found that tetracycline-induced YB-1 overexpression for a sustained
period of time led to increased expression of cyclin E and subsequent slippage through the G1/S
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checkpoint [41]. In the same paper, IF analysis found that YB-1 localised to the centrosome forming
a complex with pericentrin and α-tubulin which was vital in maintaining structural integrity and
microtubule nucleation capacity of the organelle. These reports suggest that YB-1 plays a principal role
in the organisation of the cytoskeleton during cell division. Our data support such a role.
The importance of YB-1 phosphorylation at serine 102 has long been known since it was recognised
as key in the transcriptional activation of oncogenic genes such as EGFR [34]. S102 has been shown to
be a target of p90 Ribosomal S6 Kinase (RSK) [35,45]. Phosphorylation of either serine 165 or 176 of
YB-1 has also been reported to activate NF-κB [37]. The atomistic modelling data presented here defines
a novel mechanistic role for serine residues 102, 165 and 176. Our data show that the phosphorylation
status of these residues is dynamic and alters the conformation of YB-1 providing a mechanism for
biomolecular recognition as detailed in [46]. Such phosphorylation-induced conformational switching
has also been reported in PAGE4, another intrinsically disordered protein [47].
We propose a model, as shown in Figure 7, where the serine residues of YB-1 are phosphorylated
in G1 leading to an increase in the accessible energy surface area of the CRS, as suggested by the 3D
structural modelling in Figure 5A. YB-1 remains cytoplasmic as the cells move from G1 through to G2,
when dephosphorylation occurs and YB-1 begins to move into the nucleus in late G2 just prior to the
onset of nuclear envelope disruption in early M (prophase), concomitantly reducing the accessibility
of the CRS and increasing the accessible energy surface of the NLS resulting in nuclear translocation.
These residues are again phosphorylated in late M (telophase), to facilitate its export to the cytoplasm
where it now (presumably) plays a role in translational regulation [48–51].
Figure 7. Proposed model of YB-1 location during cell cycle phases. YB-1 is shown in yellow.
The phosphorylation status of YB-1 is depicted by the orange blocks below the cell graphic. In G1
phosphorylated YB-1 is cytoplasmic and becomes increasingly perinuclear as the cell moves from
G1/S/G2. Just prior to the breakdown of the nuclear membrane in late G2 (represented by the broken
magenta line), YB-1 is dephosphorylated, increasing the accessibility of the NLS enabling its movement
into the nucleus where it remains during mitosis until the nuclear envelope is re-established in late
telophase. Following phosphorylation and increased accessibility of the CRS, YB-1 moves to the
cytoplasmic compartment. The mitotic spindle is depicted in green; chromosomes in light blue.
This model supports previously published data [7], where removal of the C-terminal region of
YB-1 was shown to lead to nuclear translocation. We suggest that the loss of the C-terminal region may
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lead to a similar conformational change in YB-1 making the NLS more accessible. It is also in agreement
with data demonstrating that nuclear translocation of YB-1 is dependent on an intact NLS [52].
4. Materials and Methods
4.1. Cell Culture
Cells obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) were
cultured in either Dulbecco's Modified Eagle Medium (DMEM)-F12 (A549, Saos-2, MDA-MB-231
and HCT116) or RPMI (H1299), Life Technologies (Thermo Fisher Scientific), Waltham, MA, USA
or Sigma (Merck), St Louis, MO, USA supplemented with 10% fetal bovine serum (FBS), in a 37 ◦C
humidified incubator under 5% CO2. The cell lines were validated for authenticity by CellBank
Australia (http://www.cellbankaustralia.com/) using STR profiling and were regularly tested and found
negative for mycoplasma contamination.
4.2. Generation of HAYB-1 FLAG and FLAGYB-1HA Expression Constructs
A haemaglutinin (HA) tag flanked by XbaI and BamHI sites was cloned into the N-terminal of
YBX1 cDNA of a pc3-DNA backbone using a pcDNA3.3-TOPO cloning kit (Thermo Fisher Scientific).
Serine to either alanine or aspartic acid mutations at specific serine residues (S102, S165, S176) were
generated in the pcDNA3.3 HA-YBX1 plasmid by site-directed mutagenesis using mutagenesis primers
(Table S8) and were subsequently amplified with a Kapa high fidelity polymerase (Kappa HiFi PCR
kit #KK2502, Roche Diagnostics, Rotkreuz, Switzerland). To introduce a FLAG tag to the 3’ end
of HA-YBX1, two unique restriction sites, an EcoR1 site near the 3’ end of YBX1 and an Xho1 site,
were used for cloning in conjunction with the TOPO-TA kit (Thermo Fisher Scientific). The DNA
removed by these nucleases was replaced with synthetic oligonucleotides. The oligonucleotides
contained compatible ends to replace the 3’ end of YBX1 with the original sequence while incorporating
an in-frame FLAG tag before the termination codon.
4.3. Generation of YB-1EBFP2 Expression Constructs
A two-stage process was used to create HA-tagged YB-1EBFP2 expression constructs.
Firstly, an oligonucleotide encoding an HA tag flanked by XhoI and HindIII 5’ and SacII/BamHI
3’ was cloned into the XhoI/BglII sites in the MCS of pEBFP2-N1 (Addgene 54595) in-frame with
EBFP2. The coding sequence of YB-1 and upstream Kozac sequence was amplified using TaKaRa
Hi Fidelity Taq and cloned upstream of the HA tag XhoI/HindIII. The pHA-YB-1 was generated
with pcDNA3.3-TOPO TA Cloning Kit (Thermo Fisher Scientific). The resulting plasmid produced a
YB-1-HA-EBFP2 (YB-1EBFP2) fusion protein under the control of the CMV promotor. All plasmids were
propagated through Stbl3 E. coli to prevent recombination and sequenced prior to experimental use.
4.4. Generation of A549 FUCCI Cell Line
FUCCI was used to identify cell cycle phases at a single cell resolution. mVenus-hGeminin
(1/110)/pCSII-EF and mCherry-hCdt1 (30/120)/pCSII-EF (a kind gift from Atsushi Miyawaki and
Hiroyuki Miyoshi) were individually packaged into lentivectors using the 2nd generation packaging
system, and the viral supernatants were used simultaneously to co-infect target cells. Three days
post-transduction, cell cultures were sorted at the Westmead Institute for Medical Research flow
cytometry core (Sydney, Australia) for mVenus fluorescence, allowed to expand for 5 to 7 days,
and sorted again for mCherry fluorescence. Proper progression of red/green coloration during cell
cycling was confirmed with live cell imaging as described below before use.
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4.5. Plasmid Transfection and Drug Treatment
Cells were transfected using Lipofectamine 3000 (LF3000, Invitrogen (Thermo Fisher Scientific,
Waltham MA, USA), distributed by Biosciences, Dublin, Ireland)) according to the manufacturer’s
instructions. For drug treatment, media were changed 24 hours post transfection, the cells were then
treated with either 100 nM Paclitaxel or 10 nM Doxorubicin in DMSO for 24 hours. DMSO was used as
a control for drug treatment. The medium containing the drug (or control) was then aspirated and the
cells were thoroughly washed in PBS prior to collection for cell fractionation for either western blotting
(6-well plates), fixation with 4% paraformaldehyde (24-well plates), or immunofluorescence (IF).
For live cell imaging A549 FUCCI cells (1 × 104) were seeded in 2mL of DMEM supplemented with
10% FBS in a 12 well plate. After overnight incubation, cells were transfected using Lipofectamine 3000
(LF3000, Invitrogen) with 250 ng of shRNA targeting the 3’UTR (sh-YB-1) in combination with 250 ng
YB-1EBFP2. Media was changed 24 hours post transfection following which the cells were monitored
over 60 hours using the live cell time lapse imaging or were harvested at 48 h for western blot.
4.6. Live Imaging and Processing of Time-Lapse Data
For live cell imaging, cells were grown in 12-well glass bottom plates (MatTek, Ashland, MA, USA).
Time lapse live cell imaging was performed on a Zeiss Cell Observer inverted wide field microscope,
with 20 × 0.8 NA air objective, at 37 ◦C, 10% CO2 and atmospheric oxygen. Image capture commenced
24 hours post transfection, with images taken every six minutes for a duration of sixty hours using
an Axiocam 506 monochromatic camera (Zeiss, Oberkochen, Germany) and Zen Blue software (v1.0,
Zeiss). A Zeiss HXP 120C mercury short-arc lamp and compatible filter cubes were used to obtain
fluorescent images and differential interference contrast (DIC) microscopy to capture brightfield images.
To achieve optimal image resolution without excessive illumination, a binning factor was applied prior
to imaging and the ambient conditions were maintained to minimize variations in optical resolution
and illumination. The acquired videos were analyzed using the Zen Blue software (v1.0, Zeiss). For all
videos, mitotic duration and outcomes were scored by eye and calculated from nuclear envelope
breakdown until cytokinesis. FUCCI videos were scored by eye, for G1 (red) and S/G2/M (green) and
EBFP2 (blue).
4.7. Cell Fractionation and Western Blotting
Cells were harvested for cell fractionation using a Cell Fractionation kit (Cell Signaling Technology,
cat #9038, Danvers, MA, USA) according to the manufacturer’s instructions with the exception
of substitution of 4× NuPage LDS for the 3× SDS loading buffer. Protein samples were then
electrophoretically separated on Bolt™ 4–12% Bis-Tris Plus Gels (Invitrogen) using MES buffer
(LiCor, Lincoln, NA, USA) and an equal amount of total protein was loaded into each lane. The Precision
Plus Protein Dual Color Standard Ladder (Bio-Rad NZ, Auckland, NZ) was used. Proteins were
transferred onto nitrocellulose membranes using iBlot2 gel transfer stacks (Invitrogen). Membranes
were blocked with Odyssey® Blocking Buffer (PBS) (LiCor) for 1 h and then incubated for 1 h
with the primary antibodies diluted in Odyssey® Blocking Buffer (PBS)/0.2% Tween20. For the
HA/FLAG western experiments shown in Figure S2B and S4 the primary antibodies used were rabbit
anti-HA (H6908 Sigma-Aldrich 1:500 and mouse anti-FLAG (Sigma-Aldrich F1804 1:500, (Merck St
Louis, MO, USA), with rabbit anti-H3 (Millipore, 1:5000, Burlington, MA, USA)) and mouse -tubulin
(Cell Signaling Technology, 1:5000) as loading controls. For the westerns to detect changes in serine
102 phosphorylation (Figure S4), TBS blocking buffer was used together with goat anti-YB-1 [25] or
rabbit anti-phospho-YB1ser102(Cell Signalling Technology) 1:1000 and mouse anti-β-actin, clone AC-15
(Sigma-Aldrich, 1:10000) as the loading control. In both sets of experiments, membranes were
subsequently incubated with the secondary antibodies (IRDye® 680RD Goat anti-Mouse IgG (LiCor)
and IRDye® 800CW Goat anti-Rabbit IgG (LiCor)) diluted in Odyssey® Blocking Buffer (TBS or
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PBS)/0.2% Tween20. Membranes were imaged on the Odyssey® CLx Imaging System (LiCor) according
to the manufacturer’s instructions. Images were quantified using ImageStudioLite (LiCor) software.
4.8. Cell Synchronization and IF Labelling
Cells were seeded onto coverslips in a 24 well plate and subsequently subjected to a double
thymidine block with 2 mM thymidine (Sigma). Following 7–8 hours release from the second block,
cells were then fixed in 4% PFA, permeabilised with 0.2% Triton X-100 (Sigma-Aldrich) and then
blocked with 10% goat or donkey serum in PBS (depending on the secondary; Sigma-Aldrich) prior to
incubation with primary antibodies in blocking solution. Primary antibodies used were rabbit anti-HA
(Sigma-Aldrich H6908, 1:1000); mouse anti Flag M2 (Sigma-Aldrich F1804, 1:1000); rabbit anti-LaminB1
(Abcam 16048, 1:250) and sheep anti-YB-1 polyclonal to an N-terminal epitope (MSSEAETQQPPAC) of
YB-1 generated in house (Cohen et al. 2010); 1:1000). Following primary incubation, cells were washed
with PBS-Tween20 (0.1%) to remove any unbound primary antibody and then incubated with either
Alexafluor-labelled secondary antibodies (goat anti-mouse 568/goat anti-rabbit 488 or goat anti-rabbit
568/goat anti-mouse 488, and (in the case of the sheep anti-YB-1) donkey anti-goat 568, all at 1:1000).
In some instances, the DNA-binding dye Hoechst 33258 (Molecular Probes 1:1000) was used to visualise
cell nuclei. Cells were then washed with PBS prior to mounting in Fluoromount-G (SouthernBiotech,
Birmingham, AL, USA) on glass slides prior to visualization using a Nikon Ti-E inverted microscope
with a 63× oil objective (N/A 1.4) and equipped with a DSRi2 CCD camera (Nikon Belmont, CA,
USA). The acquired images were analysed using both NIS elements (Nikon) and Fiji2. In addition, a
Lionheart FX Automated Live Cell Imager (BioTek, Winooski, VT, USA) equipped with a 20 × 0.45 NA
air objective was used to collect data from multiple cells on these slides (at least 100 cells per image)
using the montaging function of Gen5 4.0 from both 365nm, 488nm and 568nm channels. Images were
then analysed for fluorescence intensity using the Dual masking capability of the same software.
4.9. Cell Proliferation Assay
Cells were treated with paclitaxel (1–1000 nM) or doxorubicin (0.01–30nM) for 48h, at which time
the media was removed and the plates were frozen at −80◦C. The plates were subsequently thawed and
the DNA content measured using a SYBR Green I-based fluorimetric assay as described previously [53].
Briefly, 100 µL of lysis buffer (10mM Tris-HCl pH 8.0, 2.5mM EDTA and 1% (vol/vol) Triton X-100)
containing 1:4000 SYBR Green I (Invitrogen) was added to the wells and the plates were incubated
overnight at 4 ◦C. The plates were mixed and the fluorescence signal for each well was measured for 1
second at an excitation of 485nm and emission of 535nm using a BioTek microplate reader (BioTek).
Growth curves were plotted as the fluorescence values at drug concentration.
4.10. Subcellular Fractionation of Cultured Cells for LC-MS/MS
Harvested cells (A549 and MDA-MB-231) were enriched into subcellular fractions as described
previously [25]. Briefly, 1 × 104 cells per µL were swollen in a hypotonic buffer (10 mM HEPES, pH
7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 1 × Complete EDTA-free), and incubated for 5 min at 4
◦C before being transferred to a Dounce homogeniser (885300-0002, 2 mL, tight pestle; 0.013–0.064
mm clearance, Kontes, Wayne, PA, USA). The Dounce was applied until 95% of the cell membranes
were ruptured and lysate was spun at 220 g for 5 min at 4 ◦C. The supernatant was collected and
stored as cytoplasmic extract. The pelleted nuclei were resuspended in 5 mL of chilled low sucrose
solution (0.25 M sucrose, 10 mM MgCl2) which was gently layered over 5 mL of chilled high sucrose
solution (0.88 M sucrose, 10 mM MgCl2). The nuclei were spun at 2800 g for 10 min at 4 ◦C to remove
contaminating cytoplasmic proteins.
4.11. Immunopurification of YB-1 and Mass Spectrometry
YB-1 was purified from the nuclear and cytoplasmic fractions of two cancer cell lines;
the adenocarcinoma cell line A549 and the breast cancer cell line MDA-MB23, as previously
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described [25]. Purified YB-1 was then separated using SDS-PAGE and stained with Coomassie
(Supplementary Figure S1B). Excised bands were analysed by LC-MS/MS to identify the proteins that
copurified with immunoprecipitated YB-1, again as previously described [25]. Peaklists and MS/MS
data were generated using the Proteome Discoverer (version 1.4) software using default settings
and searched against the Human Swiss-Prot amino acid sequence database using both the Mascot
(http://www.matrixscience.com) and Sequest (Thermo Scientific) search engines. The search was set
up for full tryptic peptides with a maximum of 3 missed cleavage sites. Carboxyamidomethyl cysteine,
oxidized methionine, deamidation (N, Q), and phosphorylation (S, T, Y) were included as variable
modifications. The precursor mass tolerance threshold was 10 ppm and the maximum fragment mass
error 0.8 Da. Peptides were accepted as identified if their false discovery rate adjusted scores were
above the score threshold at a false discovery rate≥ 1% as assessed by the Percolator algorithm [54].
Proteins were considered identified when they were assigned ≥ 2 peptides above the aforementioned
score threshold.
4.12. siRNA Transfection
Cells were reverse transfected with stealth modified 25 bp duplex siRNAs targeted to YB-1
(si-YB-1 [21]); or a scrambled control siRNA (si-Control [53] primer sequences detailed in Figure 6 legend)
both from Invitrogen. The control siRNA has no known human mRNA targets [53]. Stealth siRNAs were
transfected at a final concentration of 5 nM using Lipofectamine RNAiMax (Invitrogen). Both siRNAs
and RNAiMax were diluted in medium without serum. After 10 minutes at room temperature, the
diluted RNAiMax was added to the siRNAs, and the mixture was incubated for a further 15 minutes.
The lipoplexes formed were added to cells. After overnight transfection, the culture medium was
replaced with medium supplemented with 10% FBS following which the cells were harvested at 48 h
for western blot.
4.13. Modelling the Structure of YB-1 Protein
In the absence of the crystal structures of full length YB-1 protein, the 3D structure was generated
using standard protein modelling methods. The full-length sequence of YB-1 was used as query to
retrieve structures of sequences with homology to YB-1 from the protein databank database using
the program BLASTp [55], however no template structure was identified for the full length protein.
Therefore, the automated I-TASSER pipeline [56,57], which uses multi-threading alignment and
iterative template fragment assembly simulations to generate a 3D structural model of the YB-1 protein.
4.14. MD Simulations
The structures of full length wild type (wt) YB-1, phosphorylated YB-1 (YB-1phos), YB-1S102A,
YB-1S165A, and YB-1S176A were modelled and subjected to molecular dynamics (MD) simulations using
the pemed.CUDA module of the program Amber18 [58]. The all atom version of the Amber 14SB force
field (ff14SB) [59] was used to model the proteins. Force field parameters for phosphorylated serine
were taken as described elsewhere [60]. The phosphate groups were assigned an overall charge of
−2e. The Xleap module of Amber18 was used to prepare the system for the MD simulations. All the
simulation systems were neutralized with appropriate numbers of counterions. Each neutralized
system was solvated in an octahedral box with TIP3P [61] water molecules, leaving at least 10 Å
between the solute atoms and the borders of the box. All MD simulations were carried out in explicit
solvent at 300K. During the simulations, the long-range electrostatic interactions were treated with the
particle mesh Ewald [62] method using a real space cutoff distance of 9 Å. The Settle [63] algorithm
was used to constrain bond vibrations involving hydrogen atoms, which allowed a time step of
2 fs during the simulations. Solvent molecules and counterions were initially relaxed using energy
minimization with restraints on the protein and inhibitor atoms. This was followed by unrestrained
energy minimization to remove any steric clashes. Subsequently the system was gradually heated
from 0 to 300 K using MD simulations with positional restraints (force constant: 50 kcal mol−1 Å−2)
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on the protein over a period of 0.25 ns allowing water molecules and ions to move freely. During an
additional 0.25 ns, the positional restraints were gradually reduced followed by a 2 ns unrestrained
MD simulation to equilibrate all the atoms. For each system, three independent MD simulations
(assigning different initial velocities) were carried out for 250 ns with conformations saved every 10 ps.
Solvent accessible surface area (SASA) of the nuclear localization signal (NLS; residues 183–205) and
cytoplasmic retention signal (CRS; residues 247–267) was calculated using the program NACCESS [64].
Simulation trajectories were visualized using VMD [65] and figures were generated using PyMOL [66].
5. Conclusions
Using quantitative confocal analysis of cells fluorescently labelled with a construct tagged at
both termini (HAYB-1FLAG), we found equal ratios of both termini present in cytoplasmic and nuclear
compartments in both drug-treated and untreated cells, suggesting that cleavage does not take place.
In confirmation, we then used mass spectrometry to reveal the presence of a tryptic peptide spanning
the proposed cleavage site. We also revealed, using live cell imaging, that the cellular location of YB-1
is linked to cell cycle phase. Full-length YB-1 is primarily cytoplasmic and begins to enter the nucleus
as cells transition through the G2/M phase of the cell cycle, coinciding with the dissolution of the
nuclear membrane. Towards the end of mitosis, with the reassembly of the nuclear membrane, YB-1 is
again excluded to the cytoplasmic compartment.
To provide insight into the mechanism underpinning the cellular location of YB-1 we then used
atomistic modelling data and molecular dynamics simulations to show that the phosphorylation status
of particular serine residues affects the conformation of YB-1 altering the accessibility of both the
nuclear localisation signal (NLS) and the cytoplasmic retention signal (CRS). We confirmed the validity
of this model by showing that YB-1 is retained in the nucleus in cells with a mutation of either serine
S102A, S165A or S176A, by confocal z-stack analysis. We also showed, using live-cell imaging that
mutation of S176 to S176D either independently or together with mutation of S165 to S165D lead to an
inability of YB-1 to enter the nucleus at mitosis. These findings are consistent with the model.
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